PYC reports Phase II success in treating degenerative blindness condition
PYC Therapeutics (ASX:PYC) has reported its investigational drug candidate, VP-001, has shown success in patients with Retinitis Pigmentosa type 11 (RP11) in Phase 1/2 clinical trials where improvements were reported by patients for up to 18 months after treatment. Listen to the HotCopper podcast...
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| WB1 | Ann: Series 2020-1 WST Trust - Class A Notes | 17/10/25 | 0 | 56 | |||
|
|||||||
| WB1 | Ann: Series 2020-1 WST Trust - Class A Notes | 17/09/25 | 0 | 114 | |||
|
|||||||
| WB1 | Ann: Series 2020-1 WST Trust - Class A Notes | 18/08/25 | 0 | 129 | |||
|
|||||||
| WB1 | Ann: Series 2020-1 WST Trust - Class A Notes | 17/07/25 | 0 | 135 | |||
|
|||||||
| WB1 | Ann: Series 2020-1 WST Trust - Class A Notes | 17/06/25 | 0 | 117 | |||
|
|||||||
| WB1 | Ann: Series 2020-1 WST Trust - Class A Notes | 19/05/25 | 0 | 151 | |||
|
|||||||
| WB1 | Ann: Series 2020-1 WST Trust - Class A Notes | 17/04/25 | 0 | 163 | |||
|
|||||||
| WB1 | Ann: Series 2020-1 WST Trust - Class A Notes | 17/03/25 | 0 | 213 | |||
|
|||||||
See All Discussions
Timeline
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
| View More | |||||
ASX News